This study examines whether a digital app can help women manage symptoms of menopause. A total of 426 women with medically confirmed menopausal symptoms are randomly assigned to either use the app in addition to their usual medical care for 24 weeks, or to continue with usual care alone. The app provides evidence-based content and exercises for multimodal menopause management. Participants are followed up over 24 weeks, with the primary outcome assessed at 12 weeks. The main goal is to evaluate whether the app improves menopause-specific quality of life.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Enrollment
426
The menopause app facilitates the implementation of multimodal self-management strategies in the daily routines of individuals with a menopausal disorder, through tools such as a symptom diary and guided interactive exercises.
Medicoles
Hanover, Germany
Menopause-specific quality of life
Assessed with the Menopause-specific Quality of Life Questionnaire (MENQOL)
Time frame: Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
Menopause-specific symptom severity
Assessed with the Menopause Rating Scale (MRS II)
Time frame: Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
Daily interference due to hot flashes
Assessed with the Hot Flash Related Daily Interference Scale (HFRDIS)
Time frame: Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
Menopause-specific impairment in daily activities
Assessed with the Activity Impairment domain of the Work Productivity and Activity Impairment-Menopause questionnaire (WPAI-Menopause)
Time frame: Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
Patient activation
Assessed with the Patient Activation Measure 13 (PAM-13)
Time frame: Changes between time point T0 (baseline) and T3 (12 weeks after baseline)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.